These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 31823689

  • 1. Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept.
    Bonafede M, Oko-Osi H, Gharaibeh M, Manjelievskaia J, Lopez-Gonzalez L, Collier DH, Stolshek BS.
    J Manag Care Spec Pharm; 2020 Feb; 26(2):211-220. PubMed ID: 31823689
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.
    Gharaibeh M, Bonafede M, McMorrow D, Hernandez EJM, Stolshek BS.
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1039-1049. PubMed ID: 32715967
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
    Harnett J, Gerber R, Gruben D, Koenig AS, Chen C.
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
    [Abstract] [Full Text] [Related]

  • 5. The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis.
    Incerti D, Hernandez EJM, Tkacz J, Jansen JP, Collier D, Gharaibeh M, Moore-Schiltz L, Stolshek BS.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1236-1242. PubMed ID: 32996384
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W.
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A.
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
    Yang M, Galebach PJ, Signorovitch JE, Garg V.
    Clin Exp Rheumatol; 2017 May; 35(5):791-798. PubMed ID: 28339358
    [Abstract] [Full Text] [Related]

  • 11. Healthcare-Related Costs Associated with Switching Subcutaneous Tumor Necrosis Factor-α Inhibitor in the Treatment of Inflammatory Arthritis: a Retrospective Study.
    Dalén J, Luttropp K, Svedbom A, Black CM, Kachroo S.
    Adv Ther; 2020 Sep; 37(9):3746-3760. PubMed ID: 32647910
    [Abstract] [Full Text] [Related]

  • 12. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
    Khilfeh I, Guyette E, Watkins J, Danielson D, Gross D, Yeung K.
    J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
    [Abstract] [Full Text] [Related]

  • 13. Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data.
    Pappas DA, Litman HJ, Lesperance T, Kricorian G, Karis E, Rebello S, Hua W, Accortt NA, Stryker S.
    Rheumatol Int; 2021 Feb; 41(2):381-390. PubMed ID: 32876744
    [Abstract] [Full Text] [Related]

  • 14. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population.
    Curtis JR, Chastek B, Becker L, Quach C, Harrison DJ, Yun H, Joseph GJ, Collier DH.
    J Manag Care Spec Pharm; 2015 Apr; 21(4):318-29. PubMed ID: 25803765
    [Abstract] [Full Text] [Related]

  • 15. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
    Gu T, Mutebi A, Stolshek BS, Tan H.
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
    [Abstract] [Full Text] [Related]

  • 20. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ.
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.